ZA974486B - Concentrated antibody formulation - Google Patents

Concentrated antibody formulation

Info

Publication number
ZA974486B
ZA974486B ZA974486A ZA974486A ZA974486B ZA 974486 B ZA974486 B ZA 974486B ZA 974486 A ZA974486 A ZA 974486A ZA 974486 A ZA974486 A ZA 974486A ZA 974486 B ZA974486 B ZA 974486B
Authority
ZA
South Africa
Prior art keywords
antibody formulation
concentrated antibody
concentrated
formulation
antibody
Prior art date
Application number
ZA974486A
Other languages
English (en)
Inventor
Julian Marcus Relton
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA974486(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA974486B publication Critical patent/ZA974486B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA974486A 1996-05-24 1997-05-22 Concentrated antibody formulation ZA974486B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9610992.1A GB9610992D0 (en) 1996-05-24 1996-05-24 Concentrated antibody preparation

Publications (1)

Publication Number Publication Date
ZA974486B true ZA974486B (en) 1998-11-23

Family

ID=10794316

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA974486A ZA974486B (en) 1996-05-24 1997-05-22 Concentrated antibody formulation

Country Status (28)

Country Link
US (1) US6252055B1 (no)
EP (1) EP0907378B1 (no)
JP (1) JP3338060B2 (no)
KR (1) KR20000015935A (no)
CN (1) CN1219882A (no)
AP (1) AP9801392A0 (no)
AR (1) AR007249A1 (no)
AT (1) ATE318146T1 (no)
AU (1) AU731950B2 (no)
BR (1) BR9709267A (no)
CA (1) CA2254983A1 (no)
CO (1) CO4850562A1 (no)
CZ (1) CZ382498A3 (no)
DE (1) DE69735295T2 (no)
EA (1) EA001860B1 (no)
ES (1) ES2258277T3 (no)
GB (1) GB9610992D0 (no)
ID (1) ID16966A (no)
IL (1) IL126940A0 (no)
IS (1) IS4892A (no)
NO (1) NO985464L (no)
NZ (1) NZ332625A (no)
PE (1) PE69098A1 (no)
PL (1) PL330111A1 (no)
TR (1) TR199802423T2 (no)
WO (1) WO1997045140A1 (no)
YU (1) YU53098A (no)
ZA (1) ZA974486B (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU4314900A (en) * 1999-04-28 2000-11-17 Yamanouchi Pharmaceutical Co., Ltd. Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
JP4812228B2 (ja) * 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6875432B2 (en) * 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6365395B1 (en) * 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2006202688B2 (en) * 2001-05-31 2009-01-22 Genentech, Inc. Stable liquid formulations of antibodies
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
MXPA04003864A (es) * 2001-10-26 2004-08-11 Immuno Rx Inc Inmunoterapia para revertir la supresion inmune.
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
US7118675B2 (en) * 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
AU2003211991B2 (en) * 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
SI2236154T1 (en) 2003-02-10 2018-08-31 Biogen Ma Inc. THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
AU2012202845B2 (en) * 2003-02-10 2014-09-04 Biogen Ma Inc. Immunoglobulin formulation and method of preparation thereof
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CN1953768B (zh) * 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
US20080038253A1 (en) * 2004-03-04 2008-02-14 Cascalho Marilia I Methods For Altering T Cell Diversity
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112885A2 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
PT1765294E (pt) * 2004-05-12 2008-12-30 Baxter Healthcare Sa Microesferas de ácido nucleico, sua produção e entrega
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
NZ561137A (en) 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
SI1928503T1 (sl) 2005-08-24 2012-11-30 Immunogen Inc Postopek za pripravo konjugatov majtansinoid protitelo
JP2009510046A (ja) 2005-09-30 2009-03-12 メドイミューン・リミテッド インターロイキン−１３抗体組成物
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
ES2401820T3 (es) * 2007-07-17 2013-04-24 F. Hoffmann - La Roche Ag Filtración de flujo tangencial variable
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CN101874040A (zh) * 2007-11-29 2010-10-27 弗·哈夫曼-拉罗切有限公司 免疫球蛋白聚集体
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2710775A1 (en) * 2007-12-28 2009-07-09 Bioinvent International Ab Formulation
EP2271382B1 (en) 2008-04-15 2013-03-13 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
RU2011140498A (ru) * 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
ES2733346T3 (es) * 2009-03-24 2019-11-28 Wyeth Llc Evaporación por membrana para generar medicamentos proteicos altamente concentrados
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9241897B2 (en) 2010-02-04 2016-01-26 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
JP6055412B2 (ja) 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
CA2815689C (en) 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
AR087953A1 (es) 2011-08-26 2014-04-30 Baxter Int Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP2727643A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Cross-flow ultrafiltration device and method for concentration of pharmaceutical compositions
CA2923844C (en) 2013-09-11 2022-07-26 Arsia Therapeutics, Inc. Liquid protein formulations containing organophosphates
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
CN106132434A (zh) * 2014-04-07 2016-11-16 西雅图基因公司 抗‑cd19抗体和抗体‑药物偶联物的稳定制剂
CN106999546A (zh) * 2014-05-01 2017-08-01 弗吉尼亚技术知识资产公司 角蛋白纳米材料及其制备方法
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3334747B1 (en) 2015-08-13 2023-09-27 Amgen Inc. Charged depth filtration of antigen-binding proteins
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US12103949B2 (en) 2018-08-14 2024-10-01 Bristol-Myers Squibb Company Protein recovery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3272680D1 (en) * 1981-05-01 1986-09-25 Miles Lab Oral pharmaceutical composition containing immune globulin
JPH01268646A (ja) * 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
CH684164A5 (de) 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
DE4211169C1 (no) * 1992-03-31 1993-06-03 Klaus Kretzschmar
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
CN100360184C (zh) * 1995-07-27 2008-01-09 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂

Also Published As

Publication number Publication date
CO4850562A1 (es) 1999-10-26
GB9610992D0 (en) 1996-07-31
AU2958997A (en) 1998-01-05
ES2258277T3 (es) 2006-08-16
CN1219882A (zh) 1999-06-16
CA2254983A1 (en) 1997-12-04
AR007249A1 (es) 1999-10-27
EP0907378A1 (en) 1999-04-14
WO1997045140A1 (en) 1997-12-04
JPH11512753A (ja) 1999-11-02
AP9801392A0 (en) 1998-12-31
IL126940A0 (en) 1999-09-22
DE69735295T2 (de) 2006-10-05
US6252055B1 (en) 2001-06-26
PE69098A1 (es) 1998-12-02
KR20000015935A (ko) 2000-03-15
EA001860B1 (ru) 2001-10-22
PL330111A1 (en) 1999-04-26
JP3338060B2 (ja) 2002-10-28
DE69735295D1 (de) 2006-04-27
NZ332625A (en) 2000-04-28
IS4892A (is) 1998-11-10
NO985464L (no) 1999-01-18
EP0907378B1 (en) 2006-02-22
YU53098A (sh) 2000-03-21
AU731950B2 (en) 2001-04-05
ID16966A (id) 1997-11-27
EA199800946A1 (ru) 1999-06-24
TR199802423T2 (xx) 1999-02-22
BR9709267A (pt) 1999-08-10
ATE318146T1 (de) 2006-03-15
CZ382498A3 (cs) 1999-05-12
NO985464D0 (no) 1998-11-23

Similar Documents

Publication Publication Date Title
ZA974486B (en) Concentrated antibody formulation
GB9603256D0 (en) Antibodies
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
HK1011856A1 (en) Cement formulation.
ZA9710601B (en) Novel formulation
HUP9800744A3 (en) Antibodies against fas-antigene
GB9724544D0 (en) Novel Formulation
GB9725061D0 (en) Revitalisation formulation
GB9706957D0 (en) Formulation
GB9615628D0 (en) Formulation
AU131132S (en) Handleset
HU9602732D0 (en) Lanperisone formulation
GB9404989D0 (en) Lipomimetric formulation
AU131131S (en) Handleset
AU131199S (en) Handleset
HUP9903547A3 (en) Concentrated antibody preparation
CA79582S (en) Jerkin
AU1593P (en) Songlines Telopea speciosissima
GB9620413D0 (en) Structural member
GB9606602D0 (en) Structural member
GB9721807D0 (en) Formulation
GB9725275D0 (en) Formulation
PL314371A1 (en) Longwall-type combined cutter-loader
PL332963A1 (en) Nalpha-2-(4-nitrophenylsulphonyl) ethoxycarboxylaminoacids
GB9624115D0 (en) Formulations